IVUS

High doses of statins may reduce the lipid content in severe injury

Original title: Changes in Plaque Lipid Content After Short-Term Intensive Versus Standard Statin Therapy. The YELLOW Trial (Reduction in Yellow Plaque by Aggressive Lipid-Lowering Therapy). Reference: Annapoorna S. Kini et al. J Am Coll Cardiol 2013;62:21–9. Multiple studies have shown the benefits of statins in reducing all events, stabilize plaques and improve endothelial function. Coronary intravascular ultrasound (IVUS)...

Colchicine could reduce restenosis in diabetic patients treated with BMS

Original title: Colchicine Treatment for the Prevention of Bare-Metal Stent Restenosis in Diabetic Patients. Reference: Spyridon Deftereos et al. J Am Coll Cardiol 2013;61:1679–85. In stent restenosis is more frequent in diabetic patients, who therefore find DES particularly beneficial. However, there is a subset of these patients with contraindication to prolonged double antiaggregation, due to a programmed surgery...

It takes more patience to implant stents.

Original title: Duration of Balloon Inflation for Optimal Stent Deployment: Five Seconds Is Not Enough. Reference: Thomas Hovasse et al. Catheterization and Cardiovascular Interventions 81:446–453 (2013). Adequate stent expansion and apposition to the vessel wall is essential to optimize the results of percutaneous transluminal coronary angioplasty (PTCA). If the above is not adequate, it increases the risk of...

Balloon Pulmonary Angioplasty (BPA) in patients with Chronic Thromboembolic Pulmonary Hypertension

Original title: Refined Balloon Pulmonary Angioplasty for Inoperable Patients with Chronic Thromboembolic Pulmonary Hypertension. Reference: Hiroki Mizoguchi et al. Circ Cardiovasc Interv. 2012;5:748-755. Patients with Chronic Thromboembolic Pulmonary Hypertension (CTE-PH) have bad prognosis. Pulmonary thromboendarterectomy can significantly reduce pulmonary pressure but, due to comorbidity or technical matters (very peripheral thrombi), not all patients are good candidates for this...

Future second-generation stents, today.

Original title: First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold A Multi-Imaging Modality Study. Reference: John Ormiston et al. Circ Cardiovasc Interv. 2012;5:620-632. The first bioabsorbable stents eluting everolimus showed a 6-month delayed recoil resulting in late lumen loss of 0.44 mm, (intermediate between a metal stent...

Top